|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.56 USD | -1.55% |
|
+0.08% | +78.23% |
| 13/03 | GSK gets US FDA approval for expanded use of RSV vaccine | RE |
| 10/03 | Moderna, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-10-2026 09:30 AM |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | $42.9 | -18.38% | 20 | ||||||
| $872.85 | +17.04% | 27 | ||||||
| €284.85 | +14.12% | 20 | ||||||
| ₩22,53,934.38 | +41.58% | 25 | ||||||
| A$145.88 | +47.74% | 16 | ||||||
| $205.67 | +13.28% | 30 | ||||||
| $108.77 | +17.54% | 22 | ||||||
| HK$102.34 | +43.97% | 26 | ||||||
| SEK 423.6 | +13.63% | 10 | ||||||
| ₩4,35,000 | +20.33% | 4 | ||||||
| $99.96 | +44.01% | 22 | ||||||
| $88.96 | +52.04% | 23 | ||||||
| $222.47 | +42.53% | 21 | ||||||
| $313.22 | +26.68% | 9 | ||||||
| - | - | CN¥50 | +25.79% | 1 | ||||
| HK$34.72 | +88.9% | 11 | ||||||
| €15.05 | +63.22% | 12 | ||||||
| - | - | - | - | - | ||||
| CN¥24.78 | +53.15% | 5 | ||||||
| Average | 1,49,553.91 | +33.73% | 17 | ||||||
| Weighted average by Cap. | 2,88,448.74 | +27.52% | 21 |
- Stock Market
- Equities
- MRNA Stock
- Sector Moderna, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition